Clinical Trials Browser

INDUSTRY × Ovarian Neoplasms × prexasertib × Clear all

NCT03414047 2022-08-19

A Study of Prexasertib (LY2606368) in Platinum-Resistant or Refractory Recurrent Ovarian Cancer

Phase 2 Completed

172 enrolled 19 charts

Ovarian Neoplasms